Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 1/20 | 0.72 |
| ▸ | BRD4 | O60885 | 11/20 | 0.68 |
| ▸ | BRD2 | P25440 | 3/20 | 0.61 |
| ▸ | BRD3 | Q15059 | 2/20 | 0.56 |
| ▸ | MLYCD | O95822 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2760349 | 0.84 | PTGS2 (1.00) | PTGS2BRD4 | |
| SCHEMBL7857274 | 0.82 | BRD4 (0.64) | PTGS2BRD4MLYCDMAPT | |
| SCHEMBL8300240 | 0.80 | BRD4 (0.70) | BRD4BRD2BRD3MLYCD | |
| SCHEMBL1670546 | 0.80 | PTGS2 (0.52) | PTGS2BRD4BRD2BRD3 | |
| SCHEMBL20578250 | 0.80 | BRD4 (0.54) | PTGS2BRD4BRD2BRD3MLYCD | |
| SCHEMBL1651941 | 0.79 | BRD4 (0.54) | PTGS2BRD4BRD2BRD3MAPT | |
| SCHEMBL12800381 | 0.79 | PTGS2 (0.51) | PTGS2BRD4BRD2BRD3 | |
| SCHEMBL22703757 | 0.79 | BRD4 (0.64) | PTGS2BRD4BRD2BRD3 | |
| SCHEMBL4586989 | 0.78 | PTGS2 (0.88) | PTGS2BRD4 | |
| SCHEMBL12800374 | 0.78 | PTGS2 (0.50) | PTGS2BRD4BRD2BRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109912584-B | BRD4 protein inhibitor with anti-tumor activity and preparation method and application thereof | 中国药科大学 | 2021-08-13 | — | — | CN | disclosed |
| CN-109912584-A | BRD4 protein inhibitor with anti-tumor activity and preparation method and application thereof | 中国药科大学 | 2019-06-21 | — | — | CN | disclosed |
| US-9975896-B2 | Inhibitors of transcription factors and uses thereof | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2018-05-22 | — | — | US | disclosed |
| US-20160168154-A1 | INHIBITORS OF TRANSCRIPTION FACTORS AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2016-06-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160168154-A1 | INHIBITORS OF TRANSCRIPTION FACTORS AND USES THEREOF | BRD4, BRPF3, EP300 | PTGS2 1594/4885BRD4 1/4885BRD2 14/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.